Lyra Therapeutics is a clinical-stage biotechnology company focused on the development and commercialization of therapies for the treatment of patients with chronic rhinosinusitis (CRS). Co.'s technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Co.'s product candidates, LYR-210, which is designed to treat CRS patients both with and without nasal polyps who have failed previous medical management and have not undergone endoscopic sinus surgery; and LYR-220, which is also designed to utilize mometasone furoate, and employs a larger matrix designed for patients whose nasal cavity is enlarged due to sinus surgery. The LYRA average annual return since 2020 is shown above.
The Average Annual Return on the LYRA average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether LYRA average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the LYRA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|